Alembic Pharmaceuticals Limited APLLTD
NSE · India · Health Technology
INR 819.00-6.45 (-0.78%)
Market open· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Consolidated revenue surged 26% YoY, driven by a 49% jump in US generics, prompting the company to raise its full-year growth outlook to mid-teens.
Alembic Pharmaceuticals Ltd (BOM:533573) reports a 4% revenue increase and strategic advancements despite ongoing pricing pressures and supply chain volatility.
Alembic Pharmaceuticals Ltd (BOM:533573) reports an 11% revenue increase, driven by strategic expansions and new product launches, despite facing pricing challenges and margin contractions.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.